公开(公告)号：US20200281960A1

公开(公告)日：2020-09-10

申请号：US16756670

申请日：2018-10-25

Applicant: MediGear International Corporation ,  TOKYO INSTITUTE OF TECHNOLOGY

Inventor： Shinae KONDOH ,  Takeo TANAKA

IPC: A61K31/717 ,  A61K31/722 ,  A61K31/77 ,  A61K47/46 ,  A61L31/06 ,  A61L31/14 ,  A61P35/00 ,  C08L1/02 ,  C08K5/1539

Abstract: The present invention is directed to provide a tumor sealant that causes no serious side effects or radiation by the agent and is used in a therapy that is an improvement of a very simple and low invasiveness therapy of starving tumor cells and makes radical cure possible. The present invention relates to a particle tumor sealant that can be injected. directly into needle-accessible tumor and that cuts off and/or isolates tumor tissue from surrounding tissue including blood vessels by permeating through blood vessels in the tumor site, selectively accumulating in and/or adhering to tumor tissue, swelling with water in the body, settling for a certain time and pressing tumor and peritumoral cells and/or blood vessels, and covering the whole tumor, or a particle tumor sealant that cuts off between blood vessels in a tumor site and tumor tissue.

公开(公告)号：US20160145605A1

公开(公告)日：2016-05-26

申请号：US14786416

申请日：2014-04-23

Applicant: TOKYO INSTITUTE OF TECHNOLOGY

Inventor： Tetsuya KADONOSONO ,  Shinae KONDOH

IPC: C12N15/10 ,  C12N9/10 ,  C07K7/08 ,  C07K7/06 ,  G01N33/68 ,  C07K14/435

CPC classification number: C12N15/1037 ,  C07K7/06 ,  C07K7/08 ,  C07K14/001 ,  C07K14/43595 ,  C07K2319/60 ,  C12N9/1088 ,  C12N15/1034 ,  C12N15/1044 ,  C12N15/1093 ,  C12Q1/37 ,  C12Y205/01018 ,  G01N33/6845 ,  G01N2333/96466

Abstract: The object of the present invention is to provide a method for screening peptide(s) highly specific to a target molecule. The object can be solved by a peptide-presenting protein wherein a peptide is presented in a presentation region consisting of the 131st to 139th amino acids in the amino acid sequence of the SEQ ID NO: 54, wherein the peptide consisting of 4 to 15 amino acids is inserted in the 131st to 139th amino acids sequence, or substituted for any of 1 to 9 amino acid(s) sequence in the 131st to 139th amino acids sequence; and a total length of an amino acid sequence corresponding to the 131st to 139th amino acids sequence is 15 or less.

Abstract translation: 本发明的目的是提供一种筛选对靶分子高度特异性的肽的方法。 该目的可以通过肽呈递蛋白来解决，其中肽在由SEQ ID NO：54的氨基酸序列中的第131个至第139个氨基酸组成的呈递区域中存在，其中由4至15个氨基 将酸插入第131至第139个氨基酸序列，或在第131至139个氨基酸序列中取代1至9个氨基酸序列中的任何一个; 对应于第131〜139位氨基酸序列的氨基酸序列的总长度为15以下。